Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

NCT06539559 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
Neoplasm Metastasis
Drug Therapy
Bevacizumab

Interventions

DRUG: Eribulin
DRUG: Bevacizumab

Sponsor

Wang Jiayu

Collaborators

[object Object]